全球细胞和基因疗法 CDMO 市场研究报告 - 2024 年至 2032 年行业分析、规模、份额、成长、趋势和预测

全球细胞和基因治疗 CDMO 市场需求预计将从 2022 年的 40.5 亿美元增至 2030 年近 293.9 亿美元，2023-2030 年研究期间CAGR为 28.11%。

细胞和基因疗法合约开发和製造组织 (CDMO) 是代表其他生物製药公司提供细胞和基因疗法开发、製造和测试服务的专业公司。细胞和基因疗法是先进的治疗方法，涉及操纵或改造患者的细胞来治疗或预防疾病。这些疗法对治疗各种疾病有着极大的希望，包括某些癌症、遗传性疾病和其他严重疾病。

市场动态

在多种因素的推动下，细胞和基因治疗合约开发和製造组织 (CDMO) 市场正在经历显着成长。作为各种疾病的创新疗法，细胞和基因疗法日益受到关注和投资，推动了对专业製造服务的需求。这些疗法涉及的製造过程非常复杂，加上对专业知识和专门设施的需求，导致外包给 CDMO 的趋势不断上升。监管支持和合规性是关键的驱动因素，因为细胞和基因疗法的严格监管要求使得经验丰富的 CDMO 在遵守标准方面拥有良好的记录而备受追捧。 CDMO 提供的灵活性和可扩展性是影响市场的重要因素，使生物製药公司能够有效地适应临床试验进展和商业化需求。随着细胞和基因治疗领域的进步，对 CDMO 服务的需求预计将继续增长，这些组织在支持创新疗法的开发和製造方面发挥着至关重要的作用。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球细胞和基因治疗 cdmo 市场的每个细分市场进行了包容性评估。细胞和基因治疗 cdmo 产业的成长和趋势为本研究提供了整体方法。

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲的细胞和基因治疗 CDMO 市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。细胞和基因疗法 CDMO 市场的主要参与者包括 Lonza、Catalent, Inc、Cytiva、Samsung Biologics、Thermo Fisher Scientific Inc.、Novartis AG、WuXi AppTec、AGC Biologics、OmniaBio、Rentschler Biopharma SE、Charles River Laboratories。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

• 报告说明
  • 客观的
  • 目标受众
  • 独特的销售主张 (USP) 和产品
• 研究范围
• 研究方法论
  • 市场研究过程
  • 市场研究方法论

第 2 章：执行摘要

• 市集亮点
• 全球市场概况

第 3 章：细胞与基因治疗 CDMO - 产业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场限制
• 机会
• 产业动态
• 波特五力分析
• 市场吸引力分析
  • 按阶段分析市场吸引力
  • 市场吸引力分析：按产品类型
  • 按指标进行的市场吸引力分析
  • 市场吸引力分析：按地区

第 4 章：价值链分析

• 价值链分析
• 原料分析
  • 原料清单
  • 原料厂商清单
  • 主要原物料价格走势
• 潜在买家名单
• 行销管道
  • 直效行销
  • 间接行销
  • 行销通路发展趋势

第 5 章：全球细胞和基因治疗 CDMO 市场分析：按阶段

• 分阶段概览
• 历史和预测数据
• 按阶段分析
• 临床前
• 临床

第 6 章：全球细胞与基因疗法 CDMO 市场分析：依产品类型

• 概述：按产品类型
• 历史和预测数据
• 分析：依产品类型
• 基因治疗（体外、体内）
• 基因修饰细胞疗法（CAR T 细胞疗法、CAR-NK 细胞疗法、TCR-T 细胞疗法、其他）
• 细胞疗法

第 7 章：全球细胞与基因疗法 CDMO 市场分析：按适应症分类

• 按适应症概述
• 历史和预测数据
• 按指标分析
• 肿瘤学
• 传染性疾病
• 神经系统疾病
• 罕见疾病
• 其他的

第 8 章：全球细胞和基因治疗 CDMO 市场分析：按地理位置

• 区域展望
• 介绍
• 北美销售分析
  • 概览、历史与预测资料销售分析
  • 北美按细分市场销售分析
  • 北美按国家销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史与预测资料销售分析
  • 欧洲按细分市场销售分析
  • 欧洲按国家销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 义大利销售分析
  • 俄罗斯销售分析
  • 欧洲其他地区销售分析
• 亚太地区销售分析
  • 概览、历史与预测资料销售分析
  • 亚太地区按细分市场销售分析
  • 亚太地区国家/地区销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本销售分析
  • 韩国销售分析
  • 澳洲销售分析
  • 东南亚销售分析
  • 亚太地区其他地区销售分析
• 拉丁美洲销售分析
  • 概览、历史与预测资料销售分析
  • 拉丁美洲按细分市场销售分析
  • 拉丁美洲按国家销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利销售分析
  • 拉丁美洲其他地区销售分析
• 中东和非洲销售分析
  • 概览、历史与预测资料销售分析
  • 中东和非洲按细分市场销售分析
  • 中东和非洲国家销售分析
  • 沙乌地阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 中东其他地区和非洲销售分析

第 9 章：细胞与基因疗法 CDMO 公司的竞争格局

• 细胞和基因治疗Cdmo市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第 10 章：公司简介

• 公司股份分析
• 市场集中度
• Lonza
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Catalent Inc
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Cytiva
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Samsung Biologics
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Thermo Fisher Scientific Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Novartis AG
• 公司简介
• 公司收入
• 产品
• 最近的发展
• WuXi AppTec
• 公司简介
• 公司收入
• 产品
• 最近的发展
• AGC Biologics
• 公司简介
• 公司收入
• 产品
• 最近的发展
• OmniaBio
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Rentschler Biopharma SE
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Charles River Laboratories
• 公司简介
• 公司收入
• 产品
• 最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

The global demand for Cell And Gene Therapy CDMO Market is presumed to reach the market size of nearly USD 29.39 BN by 2030 from USD 4.05 BN in 2022 with a CAGR of 28.11% under the study period 2023 - 2030.

Cell and Gene Therapy Contract Development and Manufacturing Organizations (CDMOs) are specialized companies that provide services for the development, manufacturing, and testing of cell and gene therapies on behalf of other biopharmaceutical companies. Cell and gene therapies are advanced therapeutic approaches that involve manipulating or engineering a patient's cells to treat or prevent diseases. These therapies hold great promise for various conditions, including certain cancers, genetic disorders, and other severe illnesses.

MARKET DYNAMICS

The Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market is experiencing significant growth driven by multiple factors. The increasing focus and investment in cell and gene therapies as innovative treatments for various diseases have propelled the demand for specialized manufacturing services. The complexity of the manufacturing process involved in these therapies, coupled with the need for expertise and specialized facilities, has led to a rising trend of outsourcing to CDMOs. Regulatory support and compliance are critical drivers, as the stringent regulatory requirements for cell and gene therapies make experienced CDMOs with a proven track record in adherence to standards highly sought after. Flexibility and scalability offered by CDMOs are essential factors influencing the market, enabling biopharmaceutical companies to adapt production to clinical trial progress and commercialization needs effectively. As the field of cell and gene therapy advances, the demand for CDMO services is expected to continue growing, with these organizations playing a crucial role in supporting the development and manufacturing of innovative therapies.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cell and gene therapy cdmo. The growth and trends of cell and gene therapy cdmo industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the cell and gene therapy cdmo market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Phase

• Pre-Clinical
• Clinical

By Product Type

• Gene Therapy (Ex-Vivo, In-Vivo)
• Gene-Modified Cell Therapy (Car T-Cell Therapies, Car-Nk Cell Therapy, Tcr-T Cell Therapy, Other)
• Cell Therapy

By Indication

• Oncology
• Infectious Diseases
• Neurological Disorders
• Rare Diseases
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cell And Gene Therapy CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cell And Gene Therapy CDMO market include Lonza, Catalent, Inc, Cytiva, Samsung Biologics, Thermo Fisher Scientific Inc., Novartis AG, WuXi AppTec, AGC Biologics, OmniaBio, Rentschler Biopharma SE, Charles River Laboratories. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . CELL AND GENE THERAPY CDMO - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Phase
  • 3.7.2 Market Attractiveness Analysis By Product Type
  • 3.7.3 Market Attractiveness Analysis By Indication
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL CELL AND GENE THERAPY CDMO MARKET ANALYSIS BY PHASE

• 5.1 Overview by Phase
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Phase
• 5.4 Pre-clinical Historic and Forecast Sales by Regions
• 5.5 Clinical Historic and Forecast Sales by Regions

6 . GLOBAL CELL AND GENE THERAPY CDMO MARKET ANALYSIS BY PRODUCT TYPE

• 6.1 Overview by Product Type
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Product Type
• 6.4 Gene Therapy (Ex-vivo, In-vivo) Historic and Forecast Sales by Regions
• 6.5 Gene-Modified Cell Therapy (CAR T-cell Therapies, CAR-NK Cell Therapy, TCR-T Cell Therapy, Other) Historic and Forecast Sales by Regions
• 6.6 Cell Therapy Historic and Forecast Sales by Regions

7 . GLOBAL CELL AND GENE THERAPY CDMO MARKET ANALYSIS BY INDICATION

• 7.1 Overview by Indication
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Indication
• 7.4 Oncology Historic and Forecast Sales by Regions
• 7.5 Infectious Diseases Historic and Forecast Sales by Regions
• 7.6 Neurological Disorders Historic and Forecast Sales by Regions
• 7.7 Rare Diseases Historic and Forecast Sales by Regions
• 7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL CELL AND GENE THERAPY CDMO MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2. North America By Segment Sales Analysis
  • 8.3.3. North America By Country Sales Analysis
  • 8.3.4. United State Sales Analysis
  • 8.3.5. Canada Sales Analysis
  • 8.3.6. Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2. Europe by Segment Sales Analysis
  • 8.4.3. Europe by Country Sales Analysis
  • 8.4.4. United Kingdom Sales Analysis
  • 8.4.5. France Sales Analysis
  • 8.4.6. Germany Sales Analysis
  • 8.4.7. Italy Sales Analysis
  • 8.4.8. Russia Sales Analysis
  • 8.4.9. Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2. Asia Pacific by Segment Sales Analysis
  • 8.5.3. Asia Pacific by Country Sales Analysis
  • 8.5.4. China Sales Analysis
  • 8.5.5. India Sales Analysis
  • 8.5.6. Japan Sales Analysis
  • 8.5.7. South Korea Sales Analysis
  • 8.5.8. Australia Sales Analysis
  • 8.5.9. South East Asia Sales Analysis
  • 8.5.10. Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2. Latin America by Segment Sales Analysis
  • 8.6.3. Latin America by Country Sales Analysis
  • 8.6.4. Brazil Sales Analysis
  • 8.6.5. Argentina Sales Analysis
  • 8.6.6. Peru Sales Analysis
  • 8.6.7. Chile Sales Analysis
  • 8.6.8. Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2. Middle East & Africa by Segment Sales Analysis
  • 8.7.3. Middle East & Africa by Country Sales Analysis
  • 8.7.4. Saudi Arabia Sales Analysis
  • 8.7.5. UAE Sales Analysis
  • 8.7.6. Israel Sales Analysis
  • 8.7.7. South Africa Sales Analysis
  • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE CELL AND GENE THERAPY CDMO COMPANIES

• 9.1. Cell And Gene Therapy Cdmo Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10 . COMPANY PROFILES OF CELL AND GENE THERAPY CDMO INDUSTRY

• 10.1. Company Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Lonza
  • 10.3.1. Company Overview
  • 10.3.2. Company Revenue
  • 10.3.3. Products
  • 10.3.4. Recent Developments
• 10.4. Catalent Inc
  • 10.4.1. Company Overview
  • 10.4.2. Company Revenue
  • 10.4.3. Products
  • 10.4.4. Recent Developments
• 10.5. Cytiva
  • 10.5.1. Company Overview
  • 10.5.2. Company Revenue
  • 10.5.3. Products
  • 10.5.4. Recent Developments
• 10.6. Samsung Biologics
  • 10.6.1. Company Overview
  • 10.6.2. Company Revenue
  • 10.6.3. Products
  • 10.6.4. Recent Developments
• 10.7. Thermo Fisher Scientific Inc.
  • 10.7.1. Company Overview
  • 10.7.2. Company Revenue
  • 10.7.3. Products
  • 10.7.4. Recent Developments
• 10.8. Novartis AG
  • 10.8.1. Company Overview
  • 10.8.2. Company Revenue
  • 10.8.3. Products
  • 10.8.4. Recent Developments
• 10.9. WuXi AppTec
  • 10.9.1. Company Overview
  • 10.9.2. Company Revenue
  • 10.9.3. Products
  • 10.9.4. Recent Developments
• 10.10. AGC Biologics
  • 10.10.1. Company Overview
  • 10.10.2. Company Revenue
  • 10.10.3. Products
  • 10.10.4. Recent Developments
• 10.11. OmniaBio
  • 10.11.1. Company Overview
  • 10.11.2. Company Revenue
  • 10.11.3. Products
  • 10.11.4. Recent Developments
• 10.12. Rentschler Biopharma SE
  • 10.12.1. Company Overview
  • 10.12.2. Company Revenue
  • 10.12.3. Products
  • 10.12.4. Recent Developments
• 10.13. Charles River Laboratories
  • 10.13.1. Company Overview
  • 10.13.2. Company Revenue
  • 10.13.3. Products
  • 10.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Phase (USD MN)
• Pre-clinical Market Sales by Geography (USD MN)
• Clinical Market Sales by Geography (USD MN)
• Analysis Market by Product Type (USD MN)
• Gene Therapy (Ex-vivo, In-vivo) Market Sales by Geography (USD MN)
• Gene-Modified Cell Therapy (CAR T-cell Therapies, CAR-NK Cell Therapy, TCR-T Cell Therapy, Other) Market Sales by Geography (USD MN)
• Cell Therapy Market Sales by Geography (USD MN)
• Analysis by Indication (USD MN)
• Oncology Market Sales by Geography (USD MN)
• Infectious Diseases Market Sales by Geography (USD MN)
• Neurological Disorders Market Sales by Geography (USD MN)
• Rare Diseases Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Cell And Gene Therapy Cdmo Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Cell And Gene Therapy Cdmo Report
• Market Research Process
• Market Research Methodology
• Global Cell And Gene Therapy Cdmo Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Phase
• Market Attractiveness Analysis by Product Type
• Market Attractiveness Analysis by Indication
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Phase (USD MN)
• Pre-clinical Market Sales by Geography (USD MN)
• Clinical Market Sales by Geography (USD MN)
• Global Market Analysis by Product Type (USD MN)
• Gene Therapy (Ex-vivo, In-vivo) Market Sales by Geography (USD MN)
• Gene-Modified Cell Therapy (CAR T-cell Therapies, CAR-NK Cell Therapy, TCR-T Cell Therapy, Other) Market Sales by Geography (USD MN)
• Cell Therapy Market Sales by Geography (USD MN)
• Global Market Analysis by Indication (USD MN)
• Oncology Market Sales by Geography (USD MN)
• Infectious Diseases Market Sales by Geography (USD MN)
• Neurological Disorders Market Sales by Geography (USD MN)
• Rare Diseases Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.